[Recommendations Onco-Urology 2010: Urothelial tumors].
christian.pfister@chu-rouen.fr
C
C
Pfister
M
M
Roupret
H
H
Wallerand
J-L
JL
Davin
H
H
Quintens
L
L
Guy
N
N
Houede
S
S
Bernardini
S
S
Larré
C
C
Mazerolles
C
C
Roy
D
D
Amsellem
F
F
Saint
J
J
Irani
M
M
Soulié
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D015653:Cystectomy; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D009392:Nephrectomy; D011994:Recombinant Proteins; D012307:Risk Factors; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000628:therapy; D014571:Urologic Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins